|
1
|
Babjuk M: Trends in bladder cancer
incidence and mortality: Success or disappointment? Eur Urol.
71:109–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wyszynski A, Tanyos SA, Rees JR, Marsit
CJ, Kelsey KT, Schned AR, Pendleton EM, Celaya MO, Zens MS, Karagas
MR and Andrew AS: Body mass and smoking are modifiable risk factors
for recurrent bladder cancer. Cancer. 120:408–414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moschini M, Dell'Oglio P, Luciano R,
Gandaglia G, Soria F, Mattei A, Klatte T, Damiano R, Shariat SF,
Salonia A, et al: Incidence and effect of variant histology on
oncological outcomes in patients with bladder cancer treated with
radical cystectomy. Urol Oncol. 35:335–341. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang C, Guo J, Chen H, Yao CJ, Zhuang DX,
Wang Y, Tang WJ, Ren G, Yao Y, Wu JS, et al: Gene mutation
profiling of primary glioblastoma through multiple tumor biopsy
guided by 1H-magnetic resonance spectroscopy. Int J Clin Exp
Pathol. 8:5327–5335. 2015.PubMed/NCBI
|
|
5
|
Chen KN, Gu ZD, Ke Y, Li JY, Shi XT and Xu
GW: Expression of 11 HOX genes is deregulated in esophageal
squamous cell carcinoma. Clin Cancer Res. 11:1044–1049.
2005.PubMed/NCBI
|
|
6
|
Jiang R, Ding L, Zhou J, Huang C, Zhang Q,
Jiang Y, Liu J, Yan Q, Zhen X, Sun J, et al: Enhanced HOXA10
sumoylation inhibits embryo implantation in women with recurrent
implantation failure. Cell Death Discov. 3:170572017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshida H, Broaddus R, Cheng W, Xie S and
Naora H: Deregulation of the HOXA10 homeobox gene in endometrial
carcinoma: Role in epithelial-mesenchymal transition. Cancer Res.
66:889–897. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen ZH, Zhao KM and Du T: HOXA10 promotes
nasopharyngeal carcinoma cell proliferation and invasion via
inducing the expression of ZIC2. Eur Rev Med Pharmacol Sci.
21:945–952. 2017.PubMed/NCBI
|
|
9
|
Han Y, Lu S, Wen YG, Yu FD, Zhu XW, Qiu
GQ, Tang HM, Peng ZH and Zhou CZ: Overexpression of HOXA10 promotes
gastric cancer cells proliferation and HOXA10(+)/CD44(+) is
potential prognostic biomarker for gastric cancer. Eur J Cell Biol.
94:642–652. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park SM, Choi EY, Bae M, Choi JK and Kim
YJ: A long-range interactive DNA methylation marker panel for the
promoters of HOXA9 and HOXA10 predicts survival in breast cancer
patients. Clin Epigenetics. 9:732017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chu MC, Selam FB and Taylor HS: HOXA10
regulates p53 expression and matrigel invasion in human breast
cancer cells. Cancer Biol Ther. 3:568–572. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van de Putte EEF, Bosschieter J, van der
Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL,
Jewett MAS, Stoehr R, et al: The World Health Organization 1973
classification system for grade is an important prognosticator in
T1 non-muscle-invasive bladder cancer. BJU INT. 122:978–985. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zarei S, Frank I, Boorjian SA, Thompson
RH, Kim S, Weight C, Tarrell R, Thapa P and Cheville JC: Prognostic
significance of measured depth of invasion of urothelial carcinoma
of the bladder compared to the 2010 American joint committee on
cancer pT2 and pT3 classifications. J Urol. 188:1706–1711. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marra L, Cantile M, Scognamiglio G,
Perdonà S, La Mantia E, Cerrone M, Gigantino V, Cillo C, Caraglia
M, Pignata S, et al: Deregulation of HOX B13 expression in urinary
bladder cancer progression. Curr Med Chem. 20:833–839. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lopez-Romero R, Marrero-Rodriguez D,
Romero-Morelos P, Villegas V, Valdivia A, Arreola H, Huerta-Padilla
V and Salcedo M: The role of developmental HOX genes in cervical
cancer. Rev Med Inst Mex Seguro Soc. 2 (Suppl 53):S188–S193.
2015.(In Spanish; Abstract available in Spanish from the
publisher).
|
|
16
|
Lopez R, Garrido E, Vazquez G, Piña P,
Pérez C, Alvarado I and Salcedo M: A subgroup of HOX Abd-B gene is
differentially expressed in cervical cancer. Int J Gynecol Cancer.
16:1289–1296. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mustafa M, Lee JY and Kim MH: CTCF
negatively regulates HOXA10 expression in breast cancer cells.
Biochem Biophys Res Commun. 467:828–834. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carrera M, Bitu CC, de Oliveira CE,
Cervigne NK, Graner E, Manninen A, Salo T and Coletta RD: HOXA10
controls proliferation, migration and invasion in oral squamous
cell carcinoma. Int J Clin Exp Pathol. 8:3613–3623. 2015.PubMed/NCBI
|
|
19
|
Tang W, Jiang Y, Mu X, Xu L, Cheng W and
Wang X: MiR-135a functions as a tumor suppressor in epithelial
ovarian cancer and regulates HOXA10 expression. Cell Signal.
26:1420–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fambrini M, Bussani C, Sorbi F, Pieralli A
and Cioni R: Methylation of the HOXA10 homeobox gene promoter is
associated with endometrial cancer: A pilot study. J Obstet
Gynaecol. 33:519–520. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bruins HM, Skinner EC, Dorin RP, Ahmadi H,
Djaladat H, Miranda G, Cai J and Daneshmand S: Incidence and
location of lymph node metastases in patients undergoing radical
cystectomy for clinical non-muscle invasive bladder cancer: Results
from a prospective lymph node mapping study. Urol Oncol. 32:13–24.
2014. View Article : Google Scholar
|
|
22
|
Abdollah F, Gandaglia G, Thuret R,
Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF,
Perrotte P, et al: Incidence, survival and mortality rates of
stage-specific bladder cancer in United States: A trend analysis.
Cancer Epidemiol. 37:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dodurga Y, Tataroglu C, Kesen Z and
Satiroglu-Tufan NL: Incidence of fibroblast growth factor receptor
3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder
cancer. Genet Mol Res. 10:86–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng W, Jiang Y, Liu C, Shen O, Tang W
and Wang X: Identification of aberrant promoter hypomethylation of
HOXA10 in ovarian cancer. J Cancer Res Clin Oncol. 136:1221–1227.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Srivastava P, Mandhani A, Kapoor R and
Mittal RD: Role of MMP-3 and MMP-9 and their haplotypes in risk of
bladder cancer in North Indian cohort. Ann Surg Oncol.
17:3068–3075. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakopoulou L, Gakiopoulou H, Zervas A,
Giannopoulou I, Constantinides C, Lazaris AC, Liapis H, Kyriakou G
and Dimopoulos C: MMP-3 mRNA and MMP-3 and MMP-1 proteins in
bladder cancer: A comparison with clinicopathologic features and
survival. Appl Immunohistochem Mol Morphol. 9:130–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ricci S, Bruzzese D and DI Carlo A:
Evaluation of MMP-2, MMP-9, TIMP-1, TIMP-2, NGAL and MMP-9/NGAL
complex in urine and sera from patients with bladder cancer. Oncol
Lett. 10:2527–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jager T, Tschirdewahn S, Vom Dorp F,
Piechotta G, Rubben H and Szarvas T: Siliconchiptechnology-based
MMP-7 analysis in urine: An option for preoperative identification
of lymph node metastasis in bladder cancer. Urologe A. 52:853–858.
2013.(In German). PubMed/NCBI
|
|
29
|
Szarvas T, Jager T, Becker M, Tschirdewahn
S, Niedworok C, Kovalszky I, Rübben H, Ergün S and vom Dorp F:
Validation of circulating MMP-7 level as an independent prognostic
marker of poor survival in urinary bladder cancer. Pathol Oncol
Res. 17:325–332. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang L, Liu XR, Liu JZ, Song YX, Zhou ZQ
and Cao BY: miR-182 selectively targets HOXA10 in goat endometrial
epithelium cells in vitro. Reprod Domest Anim. 52:1081–1092. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiao ZD, Jiao CY, Huang HT, He LJ, Zhao
JJ, Lu ZY and Liu LX: miR-218 modulate hepatocellular carcinoma
cell proliferation through PTEN/AKT/PI3K pathway and HoxA10. Int J
Clin Exp Pathol. 7:4039–4044. 2014.PubMed/NCBI
|
